Human HLA-A*02:01 NY-ESO-1 (SLLMWITQV) Tetramer Protein
| Specifications | |
|---|---|
| Category: | Other Recombinant Proteins |
| Molecular Weight: | 36.3 kDa, 13.8 kDa and 13.3 kDa |
| Tag: | C-10×His |
| Label / Conjugate: | N/A |
| Source: | Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (HL1-H52E7) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQV peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & SLLMWITQV). |
| Purity: | 90% |
| Endotoxin Level: | 1.0 EU per μg |
| Format: | Powder |
| Additional Information | |
|---|---|
| Synonyms: | HLA-A*02:01 & B2M & NY-ESO-1 |
| Organism: | Human |
| Accn. No.: | AAA59606.1 |
Sequence Information
Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQV peptide
Background
NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.
Price
416,00 €
